Summary tables comparing neoplastic disorders: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 13: | Line 13: | ||
|colspan="1" style = "width: 8%; background:#006699;color:white;font-size:80%"|40:80 '''wk''' | |colspan="1" style = "width: 8%; background:#006699;color:white;font-size:80%"|40:80 '''wk''' | ||
|colspan="1" style = "width: 8%; background:#004466;color:white;font-size:80%"|>80 | |colspan="1" style = "width: 8%; background:#004466;color:white;font-size:80%"|>80 | ||
|colspan="1" style = "width: 8%; background:#006699;color:white;font-size:80%"|40:80 | |colspan="1" style = "width: 8%; background:#006699;color:white;font-size:80%"|40:80 | ||
|colspan="1" style = "width: 8%; background:#004466;color:white;font-size:80%"|>80 | |||
|- | |- | ||
|colspan="1" style = "font-size:90%; color:black;" |'''FMC7''' | |colspan="1" style = "font-size:90%; color:black;" |'''FMC7''' |
Revision as of 23:58, 21 June 2023
Immunophenotype LPD | ||||
---|---|---|---|---|
Marker | CLL | MCL | FL | MZL |
κ/λ | 40:80 wk | >80 | 40:80 | >80 |
FMC7 | 20:40 wk | 40:80 | 40:80 | |
CD5 | >80 | >80 longer | <5% | |
CD10 | 5-20 | 5-20 | >80 Stg | |
CD11C | 20:40 wk | 20:40 wk | <5% | |
CD19 | >80 | >80 | 40:80 | |
CD20 | >80 | >80 | >80 | |
CD23 | >80 | 5-20 | 40:80 | |
CD25 | 20:40 wk | 20:40 wk | 5-20 wk | |
CD38 | 20:40 | >80 | >80 | |
CD43 | >80 | 40:80 | <5% | |
CD79b | >80 wk | >80 | >80 | |
CD103 | <5% | <5% | <5% | |
CD138 | <5% | <5% | <5% | |
CD200 | >80 | <5% | <5% |
Key to table:
Key to colour code Click for link
Key to expression code Click for link